ReviewDrugs2012
Management of small cell lung cancer: recent developments for optimal care.
Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Progress and application of lung-on-a-chip for lung cancer.Frontiers in bioengineering and biotechnology · 2024Review
- AntigeneCancers · 2023Article
- DHODH and cancer: promising prospects to be explored.Cancer & metabolism · 2021Review
- A Novel Graph Neural Network Methodology to Investigate Dihydroorotate Dehydrogenase Inhibitors in Small Cell Lung Cancer.Biomolecules · 2021Article
- The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Identification of DHODH as a therapeutic target in small cell lung cancer.Science translational medicine · 2019Article
- Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.BMC pulmonary medicine · 2019Observational
- Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.Cancer medicine · 2019Article
- Role of Chemosensory TRP Channels in Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.Cancer research · 2018Article
- Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.Oncotarget · 2018Article
- Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy bothOncotarget · 2017Article
- A study on different therapies and prognosis-related factors for 101 patients with SCLC and brain metastases.Cancer biology & therapy · 2017Article
- Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.Oncotarget · 2016Article
- A Novel Technique to Detect EGFR Mutations in Lung Cancer.International journal of molecular sciences · 2016Article
- Treatment for small cell lung cancer, where are we now?-a review.Translational lung cancer research · 2016Review
- High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.Lung Cancer (Auckland, N.Z.) · 2016Article
- Efficacy of 3D conformal thoracic radiotherapy for extensive-stage small-cell lung cancer: A retrospective study.Experimental and therapeutic medicine · 2015Article
- Febrile neutropenia in chemotherapy treated small-cell lung cancer patients.Radiology and oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) represents approximately 13% of all lung cancer diagnoses and the incidence has reduced over the last 20 years. Treatment of SCLC remains challenging because of its rapid growth, early dissemination and development of drug resistance during the course of the disease. Chemotherapy remains the cornerstone of treatment for limited (LD) and extensive disease (ED), with concurrent chemotherapy and radical thoracic radiotherapy representing the best treatment option for fit patients with LD. Platinum-based chemotherapy is the treatment of choice in fit patients with good organ function, and the radiosensitizing effect of cisplatin is critically important for concurrent chemoradiotherapy in LD. Anthracycline-containing regimens represent a viable alternative for patients where platinum-based chemotherapy is contraindicated. Patients who relapse or progress after first-line chemotherapy have a very poor prognosis. Second-line therapy may produce a modest clinical benefit. Maintenance chemotherapy has not been shown to convincingly improve outcomes for SCLC. A number of targeted agents have been investigated in LD and ED, mostly in unselected populations, with disappointing results. Prophylactic cranial irradiation has been shown to reduce the incidence of brain metastases and prolong survival for both LD and ED without negative impact on quality of life (QOL) and cognitive function. Ongoing trials will shed some light on the impact of thoracic radiotherapy on QOL, symptom control and survival in ED SCLC patients who benefitted from first-line chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.